GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chemomab Therapeutics Ltd DRC CMMB · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.31

-0.76%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Chemomab Therapeutics Ltd DRC

From its filings with the US Securities and Exchange Commission

SEC filings

Chemomab Therapeutics Ltd DRC is based in Tel Aviv and is incorporated in Israel. Its shares trade on Nasdaq under the ticker CMMB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2022, it reported a net loss of $27.6m. At that date it held total assets of $43.1m and shareholders' equity of $36.2m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
12 Feb 2019
Employees
12
Head office
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Incorporated in
L3
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Nebokitug is a humanized monoclonal antibody targeting inflammatory pathways.
  • The product completed phase 2 trials for primary sclerosing cholangitis.
  • Phase 2 clinical trials are ongoing for systemic sclerosis treatment.

Weaknesses

  • The company employs only twelve staff members globally.
  • Chemomab Therapeutics Ltd is a small clinical-stage biotechnology firm.
  • Operations are concentrated in Tel Aviv-Yafo, Israel, limiting scale.

Opportunities

  • Expanding nebokitug indications could address other fibrotic diseases effectively.
  • Successful phase 2 results may attract strategic partnership deals.
  • Growing demand for therapies targeting inflammatory conditions offers growth.

Threats

  • Competitors may develop superior treatments for primary sclerosing cholangitis.
  • Regulatory hurdles could delay approval for systemic sclerosis trials.
  • High research costs might strain the small employee budget.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.